129784668090053750_66Beer reports of hepatitis b vaccine fails final release without periodic
Chongqing brewery stood me up after all. Announced on April 6 was Chongqing beer days of finalizing the hepatitis b vaccine clinical study reports
tera gold, but the company is at the end of last week's announcement that, at present, the company does not know when to publish final. Chongqing brewery said, alone is leader of a group of clinical trial summary report is unit confirmed the signing process, the company will do its utmost toCoordination of efforts and urge the relevant parties to be made within 10 working days alone is a group of clinical trial summary report. This is not the first Chongqing beer fails. The end of November last year, Chongqing Brewery's shares in vaccine dream achieved with the support of the most insane moments, breaking the $ 80 mark. When the company announced that stocks will be held from November 28, 20112nd suspension, December 5 bulletin "Unblinding" resumption after work-related information. However, wait until the day I was supposed to resume trading, Chongqing brewery "in important information is being verified," continuous on the suspension.
On December 8, but revealed a direct share price fell continuously thrown beer "Unblinding" results. On December 13 last year, Chongqing brewery said is expected to separateStudy on clinical medication summary final report will be issued on April 6 this year, and shortly after
tera gold, the company rebound in share prices began to fall. Market participants pointed out at that time, Chongqing Brewery has the risk of collapse in the basic release, if relatively optimistic about the information contained in the summary report, date of the Chongqing beer may also be turned over. After experienced a strong rebound in Chongqing beer, the original meterAnnounced on April 6, and the results will be very compelling. However, the investor is the Chongqing brewery fails a second time. It is worth mentioning that, said a report published shortly before heavy beer, this clinical trial summary report could determine future vaccine research. Corporate under alone Group clinical trial summary report on whether to continue the clinical studies inEvaluation, follow-up study is significant uncertainty; combined group research and development process is still a greater risk, with significant uncertainties. On Friday
tera power leveling, the Chongqing brewery rose 1.72%, reported revenue of $ 28.33.
Others:
No comments:
Post a Comment